Jaguar Health (NASDAQ: JAGX) is a commercial stage pharmaceuticals company focused on developing novel, plant-based, and sustainably derived prescription medicines for people and animals with GI distress. The company’s wholly owned subsidiary, Napo Pharmaceuticals (Napo), focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Napo’s Mytesi(R) (crofelemer) product is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar’s crofelemer drug product candidate is also the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy. Canalevia(R)-CA1 (crofelemer delayed-release tablets), the company’s prescription drug product for the treatment of chemotherapy-induced diarrhea (“CID”) in dogs, received conditional approval from the FDA on December 21, 2021. Jaguar is the majority shareholder of Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italian corporation established by Jaguar in Milan, Italy in 2021 that focuses on expanding crofelemer access in Europe. For more information, visit the company’s website at https://jaguar.health.
To view the webcast recording of the investor presentation conducted by Jaguar’s founder, CEO, and president, Lisa Conte, at NobleCon18 on April 21, 2022, click here.
To view IBN’s virtual coverage of Noble’s 18th annual small and micro-cap investor conference, visit https://ibn.fm/NobleCon18
Important Safety Information About Mytesi
Mytesi is not approved to treat infectious diarrhea. Before you start Mytesi, you and your doctor should make sure that your diarrhea is not caused by any infection from bacteria, viruses, or parasites. If infectious diarrhea is not ruled out, there is a risk that patients with an underlying infection will not receive the appropriate therapy and the cause of the infection may worsen.
The most common side effects of Mytesi include: Upper respiratory tract infections (such as sinus, nose and throat infections), bronchitis (swelling in the tubes that carry air to and from your lungs), cough, flatulence (gas), increased bilirubin (a waste product from the breakdown of red blood cells). For a full list of side effects, please talk to your doctor. Tell your doctor if you have any side effect that bothers you or does not go away. Tell your doctor about any prescription or over-the-counter medicine, herbal supplements, or vitamins that you are taking before starting Mytesi. You may report side effects by contacting the Mytesi Call Center at 1-844-722-8256 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Important Safety Information About Canalevia-CA1
For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.
Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.
About IBN’s Virtual Coverage
The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is providing the online investment community with a custom-built portal that includes summaries on each of the publicly traded companies participating at this year’s NobleCon. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN is using social media and syndicated articles to maximize the visibility of the event.
For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com
